| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb12a064f514f0876c511fc78fbabcad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C309-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C309-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate |
2017-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea3261383858f99e1ac4c5a992fec877
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9387bd86da4a6334cd5cecf49edc080
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5160d00cf2c746591226147fa9f397cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4889c86be3f56d936106826da5d7e247
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70c69e7edcb53c24d6f159b41b6b77c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56ba6429b43d171ef947827388d2c45b |
| publicationDate |
2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190018494-A |
| titleOfInvention |
Yl) amino) phenyl) -phenyl] -4-methoxy-5 - ((4- (1 -methyl-1 H- indol-3-yl) pyrimidin- ) ≪ / RTI > acrylamide and its crystalline form |
| abstract |
(2- (2- (dimethylamino) ethoxy) -4-methoxypyridine, which is useful in the treatment or prevention of diseases or medical conditions mediated through a mutated form of epidermal growth factor receptor (EGFR) (1) and a pharmaceutically acceptable salt thereof, and a composition therefor, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula < RTI ID = 0.0 & . |
| priorityDate |
2016-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |